PRO57 COST MINIMIZATION ANALYSIS OF EMICIZUMAB IN THE PROPHYLAXIS OF INHIBITOR-NEGATIVE PATIENTS WITH HEMOPHILIA A IN TURKEY.

While the average direct cost per patient per year was calculated as €106.981,20 with Emicizumab prophylaxis for the treatment of inhibitor-negative patients with hemophilia A, it was calculated as €117.140,70 with FVIII prophylaxis and €404.385 with episodic treatment. Compared to episodic treatment (€ -297.404) and prophylactic treatment (€ -10.160) with FVIII, Emicizumab prophylaxis is found to be a less costly treatment option and to be a cost-minimizing treatment. Prophylactic treatment of Emicizumab for inhibitor-negative patients with hemophilia A is a less costly treatment and is an option to reduce the cost burden to SSI compared to other treatments. [Extracted from the article]